Studies with intravenous sodium cyanate in patients with sickle cell anemia.
D000293:Adolescent; D000328:Adult; D000596:Amino Acids / Q000032:analysis; D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D001772:Blood Cell Count; D002849:Chromatography, Gas; D002986:Clinical Trials as Topic; D003485:Cyanates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004231:Diuresis; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006827:Hydantoins; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012156:Reticulocytes / Q000187:drug effects; D013972:Thyrotropin / Q000097:blood; D013997:Time Factors; D014633:Valine / Q000032:analysis; D014667:Vasopressins / Q000097:blood
D000596:Amino Acids; D003485:Cyanates; D006454:Hemoglobins; D006827:Hydantoins; D014667:Vasopressins; D013972:Thyrotropin; D014633:Valine